Keryx Biopharmaceuticals (KERX) Up 30%

September 16, 2009 · Filed Under fda 

Keryx Biopharmaceuticals (KERX) is trading up 30% to $2.11 a 52-week high against a low of $.09 for the period.

KERX announced that KRX-0401 (perifosine) has received Orphan-Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma. In August, the Company announced that it had reached an agreement with the FDA regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial in relapsed/refractory multiple myeloma and that the study is expected to start by year-end.

Douglas A. McIntyre

Tags:

Comments

Comments are closed.

    Subscribe to BioHealth Investor BioHealth Investor RSS Feed